Enhancing Health Outcomes Among HIV+ Substance Abusers

改善艾滋病毒药物滥用者的健康状况

基本信息

批准号：
7675447
负责人：
FREDERICK LEWIS ALTICE
金额：
$ 17.97万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-09-01 至 2013-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7675447
关键词：
AIDS prevention Adherence Affect Area Award Awareness Belief Books CD4 Lymphocyte Count Caring Case Management Centers for Disease Control and Prevention (U.S.)Characteristics Communicable Diseases Communities Data Sources Drops Drug Industry Drug usage Drug user Eastern Europe Enrollment Epidemiology Evidence based intervention Foundations Funding Future Goals Grant HIV Health Health Services Healthcare Healthcare Systems Homelessness Illicit Drugs Individual International Intervention Intervention Studies Interview Jail Manuscripts Measures Mentored Patient-Oriented Research Career Development Award Mentors Mentorship National Institute of Drug Abuse Outcome Outcome Measure Paper Participant Peer Review Perception Pharmaceutical Preparations Population Prevention strategy Prisoner Prisons Process Productivity Professional Organizations Randomized Records Relapse Research Research Design Research Personnel Resources Risk Risk Reduction Schedule Southeastern Asia Structure Substance abuse problem Time United States Health Resources and Services Administration United States Substance Abuse and Mental Health Services Administration Upper arm Work base career career development clinical care community setting directly administered antiretroviral therapy follow-up meetings novel patient oriented research programs satisfaction substance abuser willingness

项目摘要

DESCRIPTION (provided by applicant): This K24 renewal application for a Mid-Career Investigator Award in Patient-Oriented Research will continue to provide me with the protected time necessary to focus my research and mentoring at the leading edge of substance abuse and infectious diseases. During the past 4 years of the current K24, I have been the PI on seven federally-funded (NIDA, SAMHSA, HRSA, CDC) awards, totaling more than $12 million. During this same time, I have co-authored 40 peer-reviewed scientific papers, six chapters in books and have been invited to present at numerous national and international meetings. I have successfully mentored many junior investigators with whom I co-author manuscripts; three have received K23 awards, one has an R21 and an R01, two have R21s under review and others received smaller grants through foundations, the pharmaceutical industry and professional organizations. Through this K24, my goals are to continue: 1) my productivity in patient-oriented research; 2) mentorship of junior investigators; and 3) to increase the awareness of the interface between substance abuse and infectious diseases. As part of this K24 application, I also intend to extend my work globally. My research to date has broadly involved epidemiological, health services outcomes and intervention studies involving drug users with or at risk for HIV. My focus has involved interventions targeting out-of-treatment drug users - primarily in community, HIV clinical care, drug treatment and correctional settings. These settings are complementary as HIV+ drug users (HIDUs) filter between these areas and each offers unique opportunities for intervention. Specifically, I am now developing NIDA-funded programs of directly administered antiretroviral therapy (DAART) in community and correctional settings and as part of prison- and jail-release programs. I am also investigating secondary HIV prevention strategies for HIDUs in these settings. I am fortunate to now be collaborating with colleagues in Eastern Europe and Southeast Asia. We are currently in the midst of developing novel treatment intervention and HIV risk-reduction research in these settings. This preliminary work will provide unique opportunities to expand evidence-based interventions and treatment globally to settings profoundly affected by drug use and infectious diseases. If allowed to continue on my current trajectory, I am likely to be able to achieve my short- and long-term career development goals.

描述（由申请人提供）：这项K24在以患者为导向的研究中为中期研究者奖的K24更新申请将继续为我提供所需的保护时间，将我的研究和指导重点放在药物滥用和感染性疾病的前沿。在当前K24的过去4年中，我一直是Federally资助的七个PI（NIDA，SAMHSA，HRSA，CDC）奖项，总计超过1200万美元。在此期间，我合着了40篇由同行评审的科学论文，书中有6章，并被邀请在众多国家和国际会议上介绍。我成功地指导了许多与我共同撰写手稿的初级调查员；三个获得了K23奖项，一项获得了R21和R01，其中有R21正在审查中，而其他人则通过基金会，制药行业和专业组织获得了较小的赠款。通过这个K24，我的目标是继续：1）我在以患者为导向的研究中的生产力； 2）初级调查人员的指导； 3）提高对药物滥用和传染病之间界面的认识。作为此K24应用程序的一部分，我还打算在全球范围内扩展工作。迄今为止，我的研究广泛涉及流行病学，卫生服务成果和干预研究，涉及患有艾滋病毒或有艾滋病毒风险的吸毒者。我的重点涉及针对治疗外吸毒者的干预措施 - 主要是在社区，艾滋病毒临床护理，药物治疗和惩教环境中。这些环境是互补的，因为艾滋病毒+吸毒者（HIDUS）在这些区域之间过滤，每个区域都提供了独特的干预机会。具体来说，我现在正在开发NIDA资助的直接管理抗逆转录病毒疗法（DAART）的计划，并作为监狱和监狱释放计划的一部分。我还正在调查这些环境中HIDUS的二级HIV预防策略。我很幸运能够与东欧和东南亚的同事合作。目前，我们正在这些环境中开发新的治疗干预措施和艾滋病毒风险研究。这项初步工作将为全球扩大基于证据的干预措施和治疗的独特机会，以受到药物使用和传染病的深刻影响。如果允许继续我目前的轨迹，我很可能能够实现我的短期和长期职业发展目标。